Laparoscopic Hysterectomy With Vaginal Vault Suspension to the Uterosacral Ligaments for Stage II-III Pelvic Organ Prolapse.

NCT ID: NCT03553511

Last Updated: 2021-09-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-31

Study Completion Date

2024-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The International Continence Society defines post-hysterectomy vault prolapse (PHVP) as descent of the vaginal cuff scar below a point that is 2 cm less than the total vaginal length above the plane of the hymen. The incidence of PHVP has been reported to affect up to 43% of hysterectomies. The risk of prolapse following hysterectomy is 5.5 times more common in women whose initial hysterectomy was for pelvic organ prolapse as opposed to other reasons.

Techniques available to manage PHVP aim to ultimately suspend the vaginal vault. Approaches include vaginal, e.g. uterosacral ligament suspension, sacrospinous ligament fixation, open procedures and more recently laparoscopic, e.g. sacrocolpopexy and uterosacral plication.

Data published so far do not allow to draw a firm conclusion about the best treatment to prevent PHVP for women undergoing hysterectomy for stage II-III pelvic organ prolapse. Considering this scenario, in the current study the investigators aim to evaluate short and long-term outcomes after total laparoscopic hysterectomy with vaginal vault suspension to the uterosacral ligaments versus vaginal hysterectomy with McCall culdoplasty for the treatment of stage II-III pelvic organ prolapse.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pelvic Organ Prolapse

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Prospective Randomized Clinical trial
Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Uterosacral ligaments suspension

Women affected by stage II-III pelvic organ prolapse undergoing total laparoscopic hysterectomy with vaginal vault suspension to the uterosacral ligaments.

Group Type EXPERIMENTAL

Vaginal vault suspension to the uterosacral ligaments

Intervention Type PROCEDURE

Laparoscopic hysterectomy with vaginal vault suspension to the uterosacral ligaments

McCall culdoplasty

Women affected by stage II-III pelvic organ prolapse undergoing vaginal hysterectomy with McCall culdoplasty.

Group Type ACTIVE_COMPARATOR

McCall culdoplasty

Intervention Type PROCEDURE

Vaginal hysterectomy with McCall culdoplasty

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vaginal vault suspension to the uterosacral ligaments

Laparoscopic hysterectomy with vaginal vault suspension to the uterosacral ligaments

Intervention Type PROCEDURE

McCall culdoplasty

Vaginal hysterectomy with McCall culdoplasty

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Stage II-III pelvic organ prolapse
* Bilateral preservation of the ovaries
* Sexually active women

Exclusion Criteria

* Smoking
* Body Mass Index \> 30
* Strenuous activity (frequent heavy lifting)
* Other gynecological and non-gynecological (chronic endocrine, metabolic, autoimmune, neoplastic diseases) comorbidities
* Pharmacological and/or nonpharmacological treatment (including pelvic floor exercises) in the six months preceding the surgery or during the study period
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Università degli Studi dell'Insubria

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Antonio Simone Laganà

Medical Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Antonio Simone Laganà, M.D.

Role: PRINCIPAL_INVESTIGATOR

Università degli Studi dell'Insubria

Jvan Casarin, M.D.

Role: PRINCIPAL_INVESTIGATOR

Università degli Studi dell'Insubria

Antonella Cromi, M.D., Ph.D.

Role: STUDY_CHAIR

Università degli Studi dell'Insubria

Fabio Ghezzi, M.D.

Role: STUDY_DIRECTOR

Università degli Studi dell'Insubria

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Antonio Simone Laganà, M.D.

Role: CONTACT

3296279579 ext. +39

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LULS-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.